Florent Puisset

42
Documents

Publications

Publications

A comparative study of gellan gum and xanthan gum versus commercial vehicles as pharmaceutical thickening agents in oral suspensions

Pauline Claraz , Luc Fillaudeau , Chloé Jadoul , Thomas Storme , Coralie Guillemot et al.
European Journal of Pharmaceutics and Biopharmaceutics, 2025, 207, pp.114622. ⟨10.1016/j.ejpb.2024.114622⟩
Article dans une revue hal-04875081 v1

Exposure-response relationship of cabozantinib in patients with metastatic renal cell carcinoma treated in routine care

Benoit Blanchet , Alexandre Xu-Vuilard , Anne Jouinot , Florent Puisset , David Combarel et al.
British Journal of Cancer, 2024, 130 (6), pp.961-969. ⟨10.1038/s41416-024-02585-y⟩
Article dans une revue hal-04920549 v1

Exposure-response relationship of cabozantinib in patients with metastatic renal cell carcinoma treated in routine care

Benoit Blanchet , Alexandre Xu-Vuilard , Anne Jouinot , Florent Puisset , David Combarel et al.
British Journal of Cancer, 2024, 130 (6), pp.961-969. ⟨10.1038/s41416-024-02585-y⟩
Article dans une revue hal-04972253 v1

Exposure toxicity of venetoclax in acute myeloid leukemia patients in the real-life setting: impact of high exposure on delayed neutropenia

Florent Puisset , Emmanuel Raffoux , Lionel Ades , Tony Huynh , Raphaël Itzykson et al.
Article dans une revue hal-04920565 v1

Exposure-response relationship of cabozantinib in patients with metastatic renal cell carcinoma treated in routine care

Benoit Blanchet , Alexandre Xu-Vuilard , Anne Jouinot , Florent Puisset , David Combarel et al.
British Journal of Cancer, 2024, 130 (6), pp.961-969. ⟨10.1038/s41416-024-02585-y⟩
Article dans une revue hal-04821736 v1

Attributes for a discrete-choice experiment on preferences of patients for oncology pharmacy consultations

Margaux Damerval , Mohammed Bennani , Catherine Rioufol , Selim Omrani , Margaux Riboulet et al.
Supportive Care in Cancer, 2024, 32 (5), pp.318. ⟨10.1007/s00520-024-08517-z⟩
Article dans une revue hal-04826152 v1

Investigating the clinical impact of dose‐banding for weekly paclitaxel in patients with breast cancer: A retrospective and monocentric study

Florent Puisset , Félicien Le Louedec , Florence Dalenc , Lorène Verguet , Eleonora de Maio et al.
British Journal of Clinical Pharmacology, 2023, 89 (7), pp.2283-2294. ⟨10.1111/bcp.15702⟩
Article dans une revue hal-04920299 v1

Investigating the clinical impact of dose‐banding for weekly paclitaxel in patients with breast cancer: A retrospective and monocentric study

Florent Puisset , Félicien Le Louedec , Florence Dalenc , Lorène Verguet , Eleonora de Maio et al.
British Journal of Clinical Pharmacology, 2023, 89 (7), pp.2283-2294. ⟨10.1111/bcp.15702⟩
Article dans une revue hal-04972257 v1

Considering the Oral Bioavailability of Protein Kinase Inhibitors: Essential in Assessing the Extent of Drug–Drug Interaction and Improving Clinical Practice

Félicien Le Louedec , Florent Puisset , Etienne Chatelut , Michel Tod
Clinical Pharmacokinetics, 2023, 62 (1), pp.55-66. ⟨10.1007/s40262-022-01200-8⟩
Article dans une revue hal-04973559 v1

Infectious risk when prescribing rituximab in patients with hypogammaglobulinemia acquired in the setting of autoimmune diseases

Xavier Boumaza , Margaux Lafaurie , Emmanuel Treiner , Ondine Walter , Gregory Pugnet et al.
International Immunopharmacology, 2023, 120, pp.110342. ⟨10.1016/j.intimp.2023.110342⟩
Article dans une revue hal-04972256 v1

Therapeutic Drug Monitoring of Tyrosine Kinase Inhibitors in the Treatment of Advanced Renal Cancer

Florent Puisset , Mourad Mseddi , Loïc Mourey , Damien Pouessel , Benoit Blanchet et al.
Cancers, 2023, 15 (1), pp.313. ⟨10.3390/cancers15010313⟩
Article dans une revue hal-04973562 v1

Retrospective, real‐life study of venetoclax plus azacitidine or low‐dose cytarabine in French patients with acute myeloid leukemia ineligible for intensive chemotherapy

Louise Laloi , Natacha Chaumard Billotey , Pierre-Yves Dumas , Franciane Paul , Alban Villate et al.
Cancer Medicine, 2022, 12 (6), pp.7175-7181. ⟨10.1002/cam4.5459⟩
Article dans une revue hal-04972259 v1
Image document

Easy and reliable maximum a posteriori Bayesian estimation of pharmacokinetic parameters with the open‐source R package mapbayr

Félicien Le Louedec , Florent Puisset , Fabienne Thomas , Étienne Chatelut , Mélanie White-Koning
CPT: Pharmacometrics and Systems Pharmacology, 2021, 10 (10), ⟨10.1002/psp4.12689⟩
Article dans une revue hal-04821229 v1

Life-threatening complications after high-dose methotrexate and the benefits of glucarpidase as salvage therapy: a cohort study of 468 patients

Chloé Medrano , Lucie Obéric , Florent Puisset , Christian Récher , Delphine Larrieu-Ciron et al.
Leukemia & lymphoma, 2021, 62 (4), pp.846 - 853. ⟨10.1080/10428194.2020.1846733⟩
Article dans une revue inserm-04791818 v1
Image document

Limited Sampling Strategy for Determination of Ibrutinib Plasma Exposure: Joint Analyses with Metabolite Data

Félicien Le Louedec , Fanny Gallais , Fabienne Thomas , Mélanie White-Koning , Ben Allal et al.
Pharmaceuticals, 2021, 14 (2), pp.162. ⟨10.3390/ph14020162⟩
Article dans une revue inserm-04791320 v1

Easy and reliable maximum a posteriori Bayesian estimation of pharmacokinetic parameters with the open‐source R package mapbayr

Félicien Le Louedec , Florent Puisset , Fabienne Thomas , Étienne Chatelut , Mélanie White-Koning
CPT: Pharmacometrics and Systems Pharmacology, 2021, 10 (10), pp.1208-1220. ⟨10.1002/psp4.12689⟩
Article dans une revue hal-04972260 v1

Severe toxicity of capecitabine in a patient with DPD deficiency after a safe FEC-100 experience: why we should test DPD deficiency in all patients before high-dose fluoropyrimidines

Maud Maillard , Audrey Eche-Gass , Mony Ung , Aurélie Brice , Sabrina Marsili et al.
Cancer Chemotherapy and Pharmacology, 2021, 87 (4), pp.579-583. ⟨10.1007/s00280-021-04233-1⟩
Article dans une revue hal-04972262 v1

Body Surface Area Dosing of High-Dose Methotrexate Should Be Reconsidered, Particularly in Overweight, Adult Patients

Fanny Gallais , Lucie Oberic , Stanislas Faguer , Suzanne Tavitian , Thierry Lafont et al.
Therapeutic Drug Monitoring, 2021, 43 (3), pp.408-415. ⟨10.1097/FTD.0000000000000813⟩
Article dans une revue hal-04973414 v1
Image document

Involvement of Pazopanib and Sunitinib Aldehyde Reactive Metabolites in Toxicity and Drug–Drug Interactions in Vitro and in Patient Samples

Marie-Noelle Paludetto , Jean-Luc Stigliani , Anne Robert , Vania Bernardes-Génisson , Etienne Chatelut et al.
Chemical Research in Toxicology, 2020, 33 (1), pp.181-190. ⟨10.1021/acs.chemrestox.9b00205⟩
Article dans une revue hal-02448694 v1

Formulae recently proposed to estimate renal glomerular filtration rate improve the prediction of carboplatin clearance

Mélanie White-Koning , Marie Noëlle Paludetto , Félicien Le Louedec , Laurence Gladieff , Christine Chevreau et al.
Cancer Chemotherapy and Pharmacology, 2020, 85 (3), pp.585-592. ⟨10.1007/s00280-019-04020-z⟩
Article dans une revue hal-04920331 v1

Brentuximab vedotin in real life, a seven year experience in patients with refractory/relapsed CD30+ T cell lymphoma

Lucie Oberic , Faustine Delzor , Caroline Protin , Sophie Perriat , Camille Laurent et al.
Journal of Oncology Pharmacy Practice, 2020, 27 (7), pp.1730-1735. ⟨10.1177/1078155220968615⟩
Article dans une revue hal-04920640 v1

Assessment of efficacy of postinfusion tubing flushing in reducing risk of cytotoxic contamination

Pauline Claraz , Isabelle Riff , Charlotte Vert , Elina Wolff , Sophie Perriat et al.
American Journal of Health-System Pharmacy, 2020, 77 (22), pp.1866-1873. ⟨10.1093/ajhp/zxaa357⟩
Article dans une revue hal-04920636 v1

Association between clinically relevant toxicities of pazopanib and sunitinib and the use of weak CYP3A4 and P-gp inhibitors

Camille Azam , Pauline Claraz , Christine Chevreau , Camille Vinson , Ewa Cottura et al.
European Journal of Clinical Pharmacology, 2020, 76 (4), pp.579-587. ⟨10.1007/s00228-020-02828-w⟩
Article dans une revue hal-04973416 v1

Life-threatening complications after high-dose methotrexate and the benefits of glucarpidase as salvage therapy: a cohort study of 468 patients

Chloé Medrano , Lucie Oberic , Florent Puisset , Christian Recher , Delphine Larrieu-Ciron et al.
Leukemia & lymphoma, 2020, 62 (4), pp.846-853. ⟨10.1080/10428194.2020.1846733⟩
Article dans une revue hal-04972263 v1

Formulae recently proposed to estimate renal glomerular filtration rate improve the prediction of carboplatin clearance

Melanie White-Koning , Marie Noëlle Paludetto , Félicien Le Louedec , Laurence Gladieff , Christine Chevreau et al.
Cancer Chemotherapy and Pharmacology, 2020, 85 (3), pp.585-592. ⟨10.1007/s00280-019-04020-z⟩
Article dans une revue hal-04973418 v1

Involvement of Pazopanib and Sunitinib Aldehyde Reactive Metabolites in Toxicity and Drug–Drug Interactions in Vitro and in Patient Samples

Marie-Noëlle Paludetto , Jean-Luc Stigliani , Anne Robert , Vania Bernardes-Génisson , Etienne Chatelut et al.
Chemical Research in Toxicology, 2019, 33 (1), pp.181-190. ⟨10.1021/acs.chemrestox.9b00205⟩
Article dans une revue hal-04973511 v1

Identifying the reactive metabolites of tyrosine kinase inhibitors in a comprehensive approach: Implications for drug‐drug interactions and hepatotoxicity

Marie-Noëlle Paludetto , Florent Puisset , Etienne Chatelut , Cécile Arellano , Marie‐noëlle Paludetto
Medicinal Research Reviews, 2019, 39 (6), pp.2105-2152. ⟨10.1002/med.21577⟩
Article dans une revue hal-04973564 v1

The prognostic impact of immune-related adverse events during anti-PD1 treatment in melanoma and non–small-cell lung cancer: a real-life retrospective study

R. Dupont , E. Bérard , F. Puisset , T. Comont , J.-P. Delord et al.
OncoImmunology, 2019, 9 (1), pp.1682383. ⟨10.1080/2162402X.2019.1682383⟩
Article dans une revue hal-04973507 v1

Simultaneous monitoring of pazopanib and its metabolites by UPLC–MS/MS

Marie-Noëlle Paludetto , Florent Puisset , Félicien Le Louedec , Ben Allal , Thierry Lafont et al.
Journal of Pharmaceutical and Biomedical Analysis, 2018, 154, pp.373-383. ⟨10.1016/j.jpba.2018.03.013⟩
Article dans une revue hal-04970346 v1

Metalloporphyrin-Catalyzed Oxidation of Sunitinib and Pazopanib, Two Anticancer Tyrosine Kinase Inhibitors: Evidence for New Potentially Toxic Metabolites

Marie-Noëlle Paludetto , Christian Bijani , Florent Puisset , Vania Bernardes-Génisson , Cécile Arellano et al.
Journal of Medicinal Chemistry, 2018, 61 (17), pp.7849-7860. ⟨10.1021/acs.jmedchem.8b00812⟩
Article dans une revue hal-04973547 v1

Metalloporphyrin-catalyzed oxidation of sunitinib and pazopanib, two anticancer tyrosine kinase inhibitors: Evidence for new potentially toxic metabolites

Marie-Noëlle Paludetto , Christian Bijani , Florent Puisset , Vania Bernardes-Génisson , C. Arellano et al.
Journal of Medicinal Chemistry, 2018, 61 (17), pp.7849-7860. ⟨10.1021/acs.jmedchem.8b00812⟩
Article dans une revue hal-01952871 v1

Safety of oral hydration after cisplatin infusion in an outpatient lung cancer unit

Florent Puisset , Laurence Bigay-Game , Marie Noëlle Paludetto , Audrey Martel , Sophie Perriat et al.
Supportive Care in Cancer, 2018, 27 (5), pp.1679-1686. ⟨10.1007/s00520-018-4415-7⟩
Article dans une revue hal-04970347 v1

Standardization of chemotherapy and individual dosing of platinum compounds.

Florent Puisset , Antonin Schmitt , Etienne Chatelut
Anticancer Research, 2014, 34 (1), pp.465-70
Article dans une revue hal-04970342 v1

The Scientific Basis of Body Surface Area–Based Dosing

E Chatelut , F Puisset
Clinical Pharmacology and Therapeutics, 2014, 95 (4), pp.359-361. ⟨10.1038/clpt.2014.7⟩
Article dans une revue hal-04970344 v1

Population pharmacokinetics of rituximab with or without plasmapheresis in kidney patients with antibody‐mediated disease

Florent Puisset , Mélanie White-Koning , Nassim Kamar , Antoine Huart , Frédérique Haberer et al.
British Journal of Clinical Pharmacology, 2013, 76 (5), pp.734-740. ⟨10.1111/bcp.12098⟩
Article dans une revue hal-04970340 v1

Dose banding as an alternative to body surface area-based dosing of chemotherapeutic agents

E Chatelut , M White-Koning , R Hj Mathijssen , F Puisset , S Baker et al.
British Journal of Cancer, 2012, 107 (7), pp.1100-1106. ⟨10.1038/bjc.2012.357⟩
Article dans une revue hal-04970339 v1

Clinical pharmacodynamic factors in docetaxel toxicity

F Puisset , J Alexandre , J-M Treluyer , V Raoul , H Roché et al.
British Journal of Cancer, 2007, 97 (3), pp.290-296. ⟨10.1038/sj.bjc.6603872⟩
Article dans une revue hal-04970337 v1

Dexamethasone as a probe for CYP3A4 metabolism: evidence of gender effect

F. Puisset , E. Chatelut , A. Sparreboom , J.-P. Delord , D. Berchery et al.
Cancer Chemotherapy and Pharmacology, 2006, 60 (2), pp.305-308. ⟨10.1007/s00280-006-0385-4⟩
Article dans une revue hal-04970336 v1

Dexamethasone as a probe for vinorelbine clearance

Florent Puisset , Florence Dalenc , Etienne Chatelut , Thierry Cresteil , Isabelle Lochon et al.
British Journal of Clinical Pharmacology, 2005, 60 (1), pp.45-53. ⟨10.1111/j.1365-2125.2005.02384.x⟩
Article dans une revue hal-04970324 v1

Dexamethasone as a probe for docetaxel clearance

Florent Puisset , Etienne Chatelut , Florence Dalenc , Florent Busi , Thierry Cresteil et al.
Cancer Chemotherapy and Pharmacology, 2004, 54 (3), pp.265-72. ⟨10.1007/s00280-004-0823-0⟩
Article dans une revue hal-04970323 v1

Pharmacocinétique

F Puisset
Pharmacie Clinique pratique en cancérologie., 2ème édition, elsevier, 2020, 9782294763755
Chapitre d'ouvrage hal-04973604 v1